摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-chloropyridin-4-yl)(phenyl)methanone | 162632-90-8

中文名称
——
中文别名
——
英文名称
(3-chloropyridin-4-yl)(phenyl)methanone
英文别名
(3-chloropyridin-4-yl)phenylmethanone;3-Chloro-pyridin-4-yl phenyl ketone;3-Chloro-4-pyridyl phenyl ketone;(3-chloropyridin-4-yl)-phenylmethanone
(3-chloropyridin-4-yl)(phenyl)methanone化学式
CAS
162632-90-8
化学式
C12H8ClNO
mdl
——
分子量
217.655
InChiKey
DILNLALJCITPPN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    343.7±22.0 °C(Predicted)
  • 密度:
    1.260±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    30
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    从相应的芳基(卤代吡啶基)甲烷酮中分三步合成3-芳基-2-磺酰胺基[2,3-b]-,-[2,3-c]-或-[3,2-c]吡啶
    摘要:
    已经开发了一种方便的三步程序,用于合成三种类型的3芳基2硫烷基噻吩并吡啶4、8和12。噻吩并[2,3- b ]吡啶衍生物4的合成的第一步是用Na 2连续处理将芳基(2-卤代吡啶-3--3-基)甲烷1中的(磺酰基甲基)硫烷基取代卤素。用S⋅9H 2 O和氯甲基硫化物制得芳基{2-[[(硫烷基甲基甲基)硫烷基]吡啶-3-基}甲酮2。在第二步中,将它们用LDA(LiN i Pr 2)处理,得到3-芳基-2,3-二氢-2-磺酰苯并[2,3- b] pyridin-3-ols 3,最后一步在吡啶存在下用SOCl 2脱水,得到所需的产物。同样,噻吩并[2,3- c ]吡啶和噻吩并[3,2- c ]吡啶衍生物8和12可以分别由芳基(3-氯吡啶-4-基)甲酮5和芳基(4-氯吡啶-3-基)甲烷9。
    DOI:
    10.1002/hlca.201200123
  • 作为产物:
    参考文献:
    名称:
    钯-N-杂环卡宾-吡啶卤化物与硼酸羰基交叉偶联的有效催化体系
    摘要:
    使用由N-杂环卡宾型配体和钯组成的催化体系,研究了不同的吡啶基卤化物与各种硼酸的羰基化交叉偶联。从相应的咪唑鎓盐和乙酸钯就地获得的这些体系,对溴代吡啶的作用似乎比基于受阻和碱性烷基膦(例如三环己基膦)的催化剂更有效。通过使用实际上不与基于膦的催化体系反应的氯或二氯吡啶和氯喹啉偶联,也证明了它们较高的效率。
    DOI:
    10.1016/j.tet.2006.11.008
点击查看最新优质反应信息

文献信息

  • Hypolipidaemic condensed 1,4-thiazepines
    申请人:Glaxo Wellcome Inc.
    公开号:US05817652A1
    公开(公告)日:1998-10-06
    The invention provides a compound of formula (I), wherein n is an integer of from 0 to 2; R is an optional substituent; R.sup.1 is hydrogen or C.sub.1-6 alkyl; R.sup.2 is an atom or group selected from hydrogen, C.sub.1-4 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.1-4 alkoxy, pyrryl, thienyl, pyridyl, 1,3-benzodioxolo, phenyl and naphthyl, which groups are optionally substituted; R.sup.3 is hydrogen, OH, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or --O C.sub.1-6 acyl; R.sup.4 is a group independently selected from C.sub.1-6 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.2-6 alkenyl, and C.sub.2-6 -alkynyl which groups are optionally substituted; R.sup.5 is a group independently selected from C.sub.2-6 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.2-6 alkenyl and C.sub.2-6 alkynyl, which groups are optionally substituted; or R.sup.4 and R.sup.5, together with the carbon atom to which they are attached, form a C.sub.3-7 spiro cycloalkyl group which is optionally substituted; R.sup.6 and R.sup.7 are independently selected from hydrogen and C.sub.1-6 alkyl; and X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein optionally one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur, or X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur; and salts, solvates and physiologically functional derivatives thereof, pharmaceutical formulations comprising such compounds, processes for their preparation and their use in reducing bile acid uptake and hence as hypolipidaemic compounds. ##STR1##
    本发明提供了一种化合物,其化学式为(I),其中n是0到2的整数;R是可选的取代基;R.sup.1是氢或C.sub.1-6烷基;R.sup.2是从氢,C.sub.1-4烷基(包括环烷基和环烷基烷基),C.sub.1-4烷氧基,吡咯基,噻吩基,吡啶基,1,3-苯并二氧杂环,苯基和萘基中选择的原子或基团,这些基团可以被取代;R.sup.3是氢,OH,C.sub.1-6烷基,C.sub.1-6烷氧基或--O C.sub.1-6酰基;R.sup.4是从C.sub.1-6烷基(包括环烷基和环烷基烷基),C.sub.2-6烯基和C.sub.2-6-炔基中独立选择的基团,这些基团可以被取代;R.sup.5是从C.sub.2-6烷基(包括环烷基和环烷基烷基),C.sub.2-6烯基和C.sub.2-6炔基中独立选择的基团,这些基团可以被取代;或R.sup.4和R.sup.5与它们连接的碳原子一起形成一个C.sub.3-7螺环烷基团,该基团可以被取代;R.sup.6和R.sup.7独立选择自氢和C.sub.1-6烷基;X是具有5到10个碳原子(包括构成噻唑环一部分的两个碳原子)的芳香或非芳香单环或双环环系,其中可选地一个或多个碳原子被氮,氧和硫独立选择的杂原子替换,或者X是具有从5到10个碳原子(包括构成噻唑环一部分的两个碳原子)的芳香或非芳香单环或双环环系,其中一个或多个碳原子被氮,氧和硫独立选择的杂原子替换;以及这些化合物的盐,溶剂化合物和生理功能衍生物,包括这样的化合物的制药组合物,它们的制备过程以及它们在减少胆汁酸吸收和因此作为降脂化合物的用途。
  • One-Pot Synthesis of 2,3-Diarylthieno[2,3-b]-, -[2,3-c]- or -[3,2-c]pyridines from the Respective Aryl(chloropyridinyl)methanones
    作者:Kazuhiro Kobayashi、Taira Ohmichi、Wataru Miyatani、Kazuhiro Nakagawa、Shohei Yuba
    DOI:10.3987/com-13-12745
    日期:——
    The title three types of 2,3-diarylthienopyridines can be conveniently prepared from the respective aryl(chloropyridinyl)methanones in one-pot. The starting ketones react with sodium sulfide nonahydrate to generate aryl[(sodiosulfanyl)pyridinyl]methanones, which are treated successively with 4-(BrCH2)C(6)H(4)EWGs and sodium hydride to give rise to the desired products in generally good yields.
  • HYPOLIPIDAEMIC CONDENSED 1,4-THIAZEPINES
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:EP0683773B1
    公开(公告)日:1997-09-17
  • US5817652A
    申请人:——
    公开号:US5817652A
    公开(公告)日:1998-10-06
  • Palladium-N-heterocyclic carbene an efficient catalytic system for the carbonylative cross-coupling of pyridine halides with boronic acids
    作者:Eddy Maerten、Mathieu Sauthier、André Mortreux、Yves Castanet
    DOI:10.1016/j.tet.2006.11.008
    日期:2007.1
    Carbonylative cross-coupling of different pyridyl halides with various boronic acids was studied using catalytic systems constituted of N-heterocyclic carbene type ligands and palladium. These systems easily obtained in situ from the corresponding imidazolium salt and palladium acetate appear more efficient toward bromopyridines than catalysts based on hindered and basic alkylphosphines such as tricyclohexylphosphine
    使用由N-杂环卡宾型配体和钯组成的催化体系,研究了不同的吡啶基卤化物与各种硼酸的羰基化交叉偶联。从相应的咪唑鎓盐和乙酸钯就地获得的这些体系,对溴代吡啶的作用似乎比基于受阻和碱性烷基膦(例如三环己基膦)的催化剂更有效。通过使用实际上不与基于膦的催化体系反应的氯或二氯吡啶和氯喹啉偶联,也证明了它们较高的效率。
查看更多